During the past decade, Well Pharma Medical Research, Corp conducted 34 clinical trials. In the 10-year time frame, 34 clinical trials started and 26 clinical trials were completed, i.e. on average, 76.5% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 19 clinical trials were completed. i.e. 105.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Well Pharma Medical Research, Corp" #1 sponsor was "Allergan" with 6 trials, followed by "Eli Lilly and Company" with 3 trials sponsored, "Incyte Corporation" with 3 trials sponsored, "Iroko Pharmaceuticals, LLC" with 3 trials sponsored and "Unity Biotechnology, Inc." with 3 trials sponsored. Other sponsors include 24 different institutions and companies that sponsored additional 29 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Well Pharma Medical Research, Corp" #1 collaborator was "Dermira, Inc." with 3 trials as a collaborator, "Allergan Sales, LLC" with 2 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "National Center for Advancing Translational Sciences (NCATS)" with 1 trials as a collaborator and "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Well Pharma Medical Research, Corp" are "Atopic Dermatitis" (5 trials), "Osteoarthritis, Knee" (4 trials), "Episodic Migraine" (3 trials), "Osteoarthritis" (3 trials) and "Chronic Gout" (2 trials). Many other conditions were trialed in "Well Pharma Medical Research, Corp" in a lesser frequency.

Most popular intervention types in "Well Pharma Medical Research, Corp" are "Drug" (43 trials), "Other" (9 trials) and "Biological" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (20 trials), "Atogepant" (3 trials), "Lebrikizumab" (3 trials), "BMS-986165" (2 trials) and "CNTX-4975-05" (2 trials). Other intervention names were less common.

The vast majority of trials in "Well Pharma Medical Research, Corp" are 44 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Well Pharma Medical Research, Corp". undefined are not yet recruiting, 5 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 32 completed trials in Well Pharma Medical Research, Corp, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Well Pharma Medical Research, Corp, 2 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 31 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".